Copyright
©The Author(s) 2016.
World J Gastroenterol. Feb 21, 2016; 22(7): 2159-2164
Published online Feb 21, 2016. doi: 10.3748/wjg.v22.i7.2159
Published online Feb 21, 2016. doi: 10.3748/wjg.v22.i7.2159
Table 1 Cyclin dependent kinases-inhibitors that have entered clinical trials
Drug name | Cyclin/CDK targeted | Manufacturer | Potential implications |
Flavopiridol | Cyclin D and CDK-4/6 | Sanofi-Aventis, Bridgewater, NJ, United States | Renal cancer, Prostate cancer, colon cancer, non-Hodgkin’s lymphoma[23] |
Cyclin E and CDK-2 | |||
Cyclin A and CDK-2 | |||
Cyclin A and CDK-1 | |||
PD-00332991 | Cyclin D and CDK-4/6 | Pfizer, New York, NY, United States | Breast cancer[25] Gastrointestinal tumors[26] |
P276-00 | Cyclin D and CDK-4/6 | Piramal Life Sciences Limited, Mumbai, India | Mantle Cell Lymphoma[27] |
Cyclin E and CDK-2 | |||
Cyclin A and CDK-2 | |||
PHA-848125 | Cyclin D and CDK-4/6 | Nerviano Medical Sciences, Nerviano, Italy | Metastatic solid tumors[27,28] |
Cyclin E and CDK-2 | |||
Cyclin A and CDK-2 | |||
LY2835219 | Cyclin D and CDK-4/6 | Eli Lilly, Indianapolis, IN, United States | Lung cancers[29] |
LEE011 | Cyclin D and CDK-4/6 | Novartis, Basel, Switzerland | Gastrointestinal cancers[30] Breast Cancer[31] |
AZD5438 | Cyclin D and CDK-4/6 | Astra Zeneca, London, England | Solid malignancies[32] |
Cyclin E and CDK-2 | |||
Cyclin A and CDK-2 | |||
Cyclin A and CDK-1 | |||
BAY 1000394 | Cyclin D and CDK-4/6 | Bayer, Barmen, Germany | Small cell lung cancer[33] |
Cyclin E and CDK-2 | |||
Cyclin A and CDK-2 | |||
Cyclin B and CDK-1 | |||
P1446A-05 | Cyclin D and CDK-4/6 | Piramal Life Sciences Limited, Mumbai, India | Advanced malignancies[34] |
SNS-032 | Cyclin E and CDK-2 | Sunesis Pharmaceutical, South San Francisco, CA, United States | Multiple myeloma, chronic lymphocytic leukemia[35] |
Cyclin A and CDK-2 | |||
Cyclin B and CDK-1 | |||
Bryostatin-1 | Cyclin E and CDK-2 | Ellisville, MO, United States | Metastatic renal cell carcinoma, soft tissue sarcoma[36] |
Cyclin A and CDK-2 | |||
Cyclin B and CDK-1 | |||
Roscovitine | Cyclin E and CDK-2 | Cyclacel Pharmaceuticals, Short Hills, NJ, United States | Advanced malignancies[37] |
Cyclin A and CDK-2 | |||
Cyclin B and CDK-1 | |||
Dinaciclib | Cyclin E and CDK-2 | Merck, Whitehouse Station, NJ, United States | Breast Cancer[38] |
Cyclin A and CDK-2 | |||
Cyclin B and CDK-1 | |||
UCN-01 | Cyclin E and CDK-2 | Sigma-Aldrich. St. Louis, MO, | Breast Cancer[39] |
Cyclin A and CDK-2 | United States | ||
Cyclin B and CDK-1 |
- Citation: Balakrishnan A, Vyas A, Deshpande K, Vyas D. Pharmacological cyclin dependent kinase inhibitors: Implications for colorectal cancer. World J Gastroenterol 2016; 22(7): 2159-2164
- URL: https://www.wjgnet.com/1007-9327/full/v22/i7/2159.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i7.2159